CA2092177A1

CA2092177A1 - Methods

Info

Publication number: CA2092177A1
Application number: CA002092177A
Authority: CA
Inventors: Alison Mary Badger
Original assignee: Individual
Current assignee: SmithKline Beecham Corp
Priority date: 1990-09-24
Filing date: 1991-09-18
Publication date: 1992-03-25
Also published as: WO1992004899A1; AU652583B2; JPH06501468A; AU8631091A; EP0550595A1; EP0550595A4

Abstract

Invented is a method of treating a disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefore amount of a substituted azaspirane.

Description

~092!Q4899 P~T/U~91/0677$
2n32~77 ' MF~Ql;2~. ';
This invention relates to a method of treating a lS disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefore amount of a substituted azaspirane.

~ack~rollnd Qf_~hs_ln~ntion Badger et al., U.S. Patent No. 4,963,557 issued October 16, 1990, (Badger) discloses compounds of the formula .:

~(C~ - N~ ,N~

3~
wher~in: n is 3-7j m is 1 or 2; R1 and R2 are the same or different and ~re selected from hydrogen or straight chain, branched chain or cyclic alkyl,-provided that.the ... , . , ~ . ... ., . . ~ . .. ., . . . , . ~ ., . . . , -, , - - . .

W092/~899 2 0 9 2 ~ 7 7 - 2 - PCT/US91/067~8 total number of carbon atoms contained by Rl and R2 when taken together is 5-lO; or Rl and R2 are joined together to form a cyclic alkyl group having 3-7 carbon atoms; R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms;
or R3 and R4 are joined together with the nitrogen atom to form a heterocyclic group having 'i-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Badger does not disclose or claim that compounds of Formula I have utility in treating disease states which are exacerbated or caused by excessive glucose levels.

Summary.nf the I~ventiQ~
This invention relates to a method of treating, prophylactically or therapeutically, a disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefore amount of a compound of the formula R2~(CI{~ N~ ~ ,N~

wherein:
n is 3~7;
m is l or 2;
Rl and R2 are the same or different and are selected from hydrogen or straight chain, branched chain or cyclic alkyl, provided that the total number of carbon atoms 35 contained by Rl and R2 when taken together is 5-lO; or Rl .:
and R2 are joined together to form a cyclic alkyl group having 3-7 carbon atoms; ~
' , .~092/04~99 - 3 - 2 ~ 9 2 1 7 7 PcT/us9l/o6778 R3 and R4 are the same or clifferent and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms;
or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Detailed Descrj~tion_of th~ I~ention The preparation of all compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates and formulations thereof is disclosed in U.S. Patent No.
4,963,557 the entire disclosure of which is hereby incorporated by reference.

As used herein, the term "compound A" refers to the dihydrochloride salt of a compound of Formula (I) where R1 and R2 are propyl, R3 and R4 are joined together with the nitrogen atom to form a saturated heterocyclic group having 5 carbon atoms, m is 1 and n is 3 which is 2~
piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4,5]decane dihydrochloride.

It has now been discovered that compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof are useful in treating, prophylactically or therapeutically, a disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human~ in need thereof. Preferably, the disease state is autoimmune diabetes mellitus.

Compound A was tested for its 1~ vivo potency in inhibiting autoimmune diabetes mellitus in rats. To perform the experiment a total of 75 Biobreeding/Worcester (BB/Wor) highly inbred (>30 generations sib-mated, and virus antibody free) diabetes-prone (diabetes appears spontaneously beginning ~60 days of age and by -120 days of age diabetes incidence reaches -85-95% in bQth sexes) rats, 27 male and 98 female (University of Massachusetts, W092/~99 - 4 - PCT/U~91/06~7~
209',~,177 Worcester, NIH Contract Colony) were used. The rats were maintained on tap water and standard laboratory chow which were available ~ lihlt~m.
The 75 rats were set up in 6 groups as follows:

Group 1 Male control, no treatment Group 2 Female control, no treatment Group 3 Male vehicle control, dosed orally once a day with vehicle alone.
Group 4 Female vehicle control, dosed orally once a day with vehicle alone.
Group 5 Male test group, dosed orally once a day with 15 mg/kg of compound A.
Group 6 Female test group, dosed oraly once a day with 15 mg/kg of compound A.

Compound A and the vehicle (0.5% gum tragacanth) were administered orally by gavage begining at age 2~ days and continuing until the age of 120 days or until the onset of diabetes. The rats were monitored daily for urine glucose. Diabetes, as used herein, is defined as glucosuria (>4+ by Testape) (Eli Lilly Canada Inc., Toronto) and a blood glucose >200mg/dl (tail vein). Blood glucose levels were determined on a Glucose Analyzer II
Beckman Instruments, Fullerton California.

The rats treated with compound A realized a significant decrease in the incidence of diabetes. Thus, the administration of a compound-of Formula I results in a therapeutic inhibition of autoimmune diabetes mellitus.

This invention relates to a method of treating a disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human, in need thereof which comprises administering an effective therefore amount of a compound of Formula tI) or a pharmaceutically acceptable salt or hydrate or solvate thereof. A compound of FormuLa (I) or a pharmaceutically :' :
, -. , , :.-;`~9~/04899 - 5 - PCT/US9J/06778 2~92177 acceptable salt or hydrate or solvate thereof can be administered to such mammal, including a human, in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger, U.S. Patent No. 4,963,557.

It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. An effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to a mammal, including a human, in need of the prevention or inhibition of excessive glucose levels in an amount sufficient to prevent or inhibit said excessive glucose levels.

The route of administration of the Formula (I) compound may be oral or parenteral. The term parenteral as used herein includes intravenous, transdermal, intramuscular, subcutaneous, intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage reglmen will preferably be from about 30 0 r 01 mg/kg to about 100 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 20 mg/kg. The daily oral dosage regimen will preferably be from about 0.5 mg to about 2000 mg.

Preferably, each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg. Preferably each oral dosage unit will ~ ~ 3 ~ ~ 7 ~ - 6 - PCT/US91/06~78 contain the active ingredient in an amount of from about 0.5 mg to about 70 mg.

While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.

It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that ~uch optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal couxse of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
., Following are the results of testing the compounds of this invention.
::.
Table I

The effect of 2-((1-piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4t5]dlecane dihydrochloride (Compound A) on inhibiting autoimmune diabetes mellitus in BB/Wor rats.
:' :
:.' .
' " '' ':

,~0 92/04899 _ 7 _ PCl/lJS9l/06778 2 0 9 217 ~
Tab1e I

Group No. Treat~nent Diabetes Incidence N=rats/group P~rcent at 120 days Group 1 None Male Control N=10 7/10 (70%) .....
Group 2 None Female Control N=13 12/13 (92~o) M+F 19123 (83%) .. _ ... _ Group 3 Vehicle Alone Male Control N=6 3/5 (60%) Group 4 Vehicle Alone Female Control N=8 7/8 (88%) . _ ...._ _ 10/13 (77%) .
Group 5 1~ m~/kg/day Male Test Group N=12 9/12 (7~;%) . -- ._ Group 6 15 mg/kglday Female Test Group N=27 10/27 (37%) . ...................... ............... ...... .... ..... _ .
. M+F 19/39 (49%) . .

The data in the above table demonstrates the :
therapeutic effect of compounds of E`ormula I on the inhibition of autoimmune diabetes mellitus.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

.. .. - -. - . - . .. - . , . . - ... - . . - -W092/04899 ~0 9 ~ 8 - PCT/US91/067~8 ; ~X~MPT.F. 1 - CAPSULE COMPOSITION
An oral dosage form for administering Formula (I) ; compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, ~elow.

ING~EpI~M~ A~OUNTS
2-((1-piperidinyl)propyl)-8,8- 50 mg dipropyl-2-azaspiro[4,5]decane dihydrochloride Lactose 110 mg Talc 32 mg Magnesium Stearate 8 mg F.XA~LE 2 - INJ~CT~BT.~ P~RE~TERAL CO~pOSITION : -An in~ectable form for administering Formula (I) compounds is produced by stirring 1.5~ by weight of 2-((1-piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4,5]decane dihydrochloride in 10% by volume propylene glycol in water.
E~m~le 3 - Composition For Administ~ation by InhaLation ~-An aerosol form for administering Formula (I) compounds is produced by dissolving 10 mg of 2-((1-piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4,5]decane dihydrochloride in ethanol (6-8 ml) and 0.1 -0.2% of a ::
lubricating agent, such as polysorbate 85 or oleic acid, in 25 an aerosol container and dispersing such mixture in a ~:
propellant, such as freon, preferably in a combination of (1,2 dichlorotetrafluoroethane) and difluorochloro methane.
:., While the above descriptions and examples fully 30 describe the invention and the preferred embodiments : -thereof, it is understood that the invention is not limited ~

!~092/04899 - 9 - PCT/US91/06778 ~2~ 77 to the particular disclosed embodiments coming within the scope of the following claims.

Claims

WO 92/04899 - 10 - PCT/US91/06??8 What is claimed is:

1. A method of prophylactically or therapeutically treating, a disease state which is exacerbated or caused by excessive glucose levels, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective therefore amount of a compound of the formula wherein:
n is 3-7;
m is 1 or 2;
R1 and R2 are the same or different and are selected from hydrogen or straight chain , branched chain or cyclic alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or R1 and R2 are joined together to form a cyclic alkyl group having 3-7 carbon atoms;
R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen to form a heterocyclic group having 5-8 atoms;
or a pharmaceutically acceptable salt or hydrate or solvate thereof.

2. The method of claim 1 wherein the disease state is autoimmune diabetes mellitus.

3. The method of claim 2 wherein the compound is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

4. The method of claim 3 wherein the compound is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride.

5. The method of claim 2 wherein the compound is 2-((1-piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4,5]decane; or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the compound is 2-((1-piperidinyl)propyl)-8,8-dipropyl-2-azaspiro[4,5]decane dihydrochloride.

7. The method according to claim 1 wherein the compound is administered orally.

8. The method according to of claim 1 wherein the compound is administered parenterally.

9. The method according to claim 1 wherein from about 0.1 to 2000 mg of compound is administered per day.

10. Use of a compound according to any one of claims 1 to 9 in the manufacture of a medicament for use in the prophylactical or therapeutical treatment of a disease state which is exacerbated or caused by excessive glucose levels.